Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Phase Ib Clinical Trial of Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma Patients

Next Previous
X
Search
Trial Profile

An Open-label, Multi-center, Phase Ib Clinical Trial of Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucidinostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Panniculitis; Peripheral T-cell lymphoma; Skin cancer; T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Chipscreen Biosciences

    • Most Recent Events

    • 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 22 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 29 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top